FDA Inspection 1040306 — Piedmont Reproductive Endocrinology Group, Pa
The FDA completed an inspection of Piedmont Reproductive Endocrinology Group, Pa on Jan 31, 2018 in Greenville, SC. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jan 31, 2018
- Fiscal Year
- 2018
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Greenville, SC (United States)